Literature DB >> 14638479

Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Elizabeth D Hermsen1, Laurie B Hovde, John R Hotchkiss, John C Rotschafer.   

Abstract

Peritoneal dialysate fluid (PDF) is a bacteriostatic medium that compromises the antibacterial activity of cell wall-active agents. By use of an in vitro static model, methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible S. aureus (MSSA), methicillin-susceptible Staphylococcus epidermidis (MSSE), and Streptococcus sanguis were exposed to daptomycin at concentrations of 10, 30, and 100 mg/liter, cefazolin at 125 mg/liter, and vancomycin at 25 mg/liter in cation-adjusted Mueller-Hinton Broth or Todd Hewitt Broth (for S. sanguis) and PDF at pHs of 5.5 and 7.4. The pH had no effect on antibacterial activity. Neither cefazolin nor vancomycin produced a bactericidal or a bacteriostatic effect versus MRSA, MSSA, MSSE, or S. sanguis in PDF, while all concentrations of daptomycin were bactericidal against all organisms in PDF. Daptomycin did not exhibit concentration-dependent activity in PDF. Daptomycin appears to be a promising agent for use in peritoneal dialysis-associated peritonitis, producing bacterial kill to a greater extent and at a higher rate than cefazolin or vancomycin in PDF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638479      PMCID: PMC296225          DOI: 10.1128/AAC.47.12.3764-3767.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Development of daptomycin for gram-positive infections.

Authors:  F P Tally; M F DeBruin
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

2.  Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.

Authors:  W F Keane; G R Bailie; E Boeschoten; R Gokal; T A Golper; C J Holmes; Y Kawaguchi; B Piraino; M Riella; S Vas
Journal:  Perit Dial Int       Date:  2000 Jul-Aug       Impact factor: 1.756

3.  Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids.

Authors:  Sheryl Zelenitsky; Christine Franczuk; Adrian Fine; Robert Ariano; Godfrey Harding
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

4.  Growth of coagulase negative staphylococci in peritoneal dialysate fluid. Effect of calcium concentration.

Authors:  A R Morton; G Evans; A Shannon; D Zoutman
Journal:  ASAIO J       Date:  1994 Jul-Sep       Impact factor: 2.872

5.  Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998.

Authors:  S Zelenitsky; L Barns; I Findlay; M Alfa; R Ariano; A Fine; G Harding
Journal:  Am J Kidney Dis       Date:  2000-11       Impact factor: 8.860

6.  Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.

Authors:  S J Davies; J Bryan; L Phillips; G I Russell
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

7.  Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis.

Authors:  Emily S Finkelstein; James Jekel; Laura Troidle; Nancy Gorban-Brennan; Fredric O Finkelstein; Frank J Bia
Journal:  Am J Kidney Dis       Date:  2002-06       Impact factor: 8.860

8.  Peritonitis influences mortality in peritoneal dialysis patients.

Authors:  L F Fried; J Bernardini; J R Johnston; B Piraino
Journal:  J Am Soc Nephrol       Date:  1996-10       Impact factor: 10.121

9.  Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study.

Authors:  R Selgas; M J Fernandez-Reyes; E Bosque; M A Bajo; F Borrego; C Jimenez; G Del Peso; F De Alvaro
Journal:  Am J Kidney Dis       Date:  1994-01       Impact factor: 8.860

10.  In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid.

Authors:  I Shalit; D F Welch; V H San Joaquin; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

View more
  19 in total

1.  Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids.

Authors:  S Tobudic; W Poeppl; C Kratzer; A Vychytil; H Burgmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-19       Impact factor: 3.267

2.  Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry.

Authors:  Nuno Cerca; Silvia Martins; Filipe Cerca; Kimberly K Jefferson; Gerald B Pier; Rosário Oliveira; Joana Azeredo
Journal:  J Antimicrob Chemother       Date:  2005-06-24       Impact factor: 5.790

3.  In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.

Authors:  Frances L Clouse; Laurie B Hovde; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

4.  Intracavitary and Systemic Daptomycin for Successful Treatment of a Postpneumonectomy Intrathoracic Infection.

Authors:  Paloma Sangro; Francisco Carmona-Torre; Miguel Mesa; Jose L Del Pozo; Jose R Yuste
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

6.  Vancomycin: the tale of the vanquisher and the pyrrhic victory.

Authors:  An S De Vriese; Stefaan J Vandecasteele
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

7.  Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.

Authors:  Carmela T M Mascio; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

8.  The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.

Authors:  M Kussmann; L Schuster; M Zeitlinger; P Pichler; G Reznicek; M Wiesholzer; H Burgmann; W Poeppl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-04       Impact factor: 3.267

9.  Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Authors:  Manuel Kussmann; Linda Schuster; Sarah Wrenger; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Perit Dial Int       Date:  2016-09-28       Impact factor: 1.756

Review 10.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.